FDA Will Cease Plasma-Derived Product Quarantine For CJD Investigations
Executive Summary
FDA will immediately release blood products quarantined for Creutzfeldt-Jakob Disease investigation, Office of Blood Research and Review Director Jay Epstein, MD, told the HHS Advisory Committee on Blood Safety and Availability Aug. 27. FDA had required manufacturers to quarantine blood and plasma-derived products while the agency investi- gated whether a donor to the blood pool from which the product was made was at increased risk of CJD.
You may also be interested in...
Plasma Derivatives Tracking, Patient Notification System Proposed By FDA
FDA intends to require tracking of plasma derivatives and other blood-derived products and notification of patients who may possess potentially infected lots.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011